Dyne Therapeutics (NASDAQ:DYN) Price Target Cut to $46.00 by Analysts at HC Wainwright
Dyne Therapeutics (NASDAQ:DYN – Free Report) had its target price reduced by HC Wainwright from $55.00 to $46.00 in a ...
What is HC Wainwright’s Estimate for IOVA Q1 Earnings?
Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Iovance Biotherapeutics in a report issued ...
Palestine Herald-Press19h
A shortage of criminal defense attorneys threatens indigent right to counsel in rural Texas
Bandera County Judge Richard Evans noticed his rolodex of criminal defense attorneys had shrunk to single digits, threatening ...
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.
SoundHound AI Says Polaris Speech Recognition Model Outperforms Google, OpenAI: Company Forays Into Energy Sector With 7-Figure Deal
SoundHound AI's speech recognition model "outperformed" Google and OpenAI during Q4 as it announced a new seven-figure energy ...
Hosted on MSN3d
HC Wainwright & Co. Downgrades LAVA Therapeutics N.V. (LVTX)
Fintel reports that on February 27, 2025, HC Wainwright & Co. downgraded their outlook for LAVA Therapeutics N.V.
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...
North American Morning Briefing: Nvidia in -2-
Minerva Neurosciences Inc (NERV) is expected to report for 4Q. NeuroMetrix Inc (NURO) is expected to report for 4Q. Nikola Corp (NKLAQ) is expected to report for 4Q. Norwegian Cruise Line Holdings Ltd ...
Fintel on MSN4d
HC Wainwright & Co. Downgrades Geron (GERN)
Fintel reports that on February 26, 2025, HC Wainwright & Co. downgraded their outlook for Geron (NasdaqGS:GERN) from Buy to ...
manilatimes5d
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies ...
BioSpace6d
FDA Shoots Down Invivyd’s Bid to Expand EUA for COVID-19 Antibody
Pemgarda has a standing emergency use authorization as a prophylaxis for immunocompromised patients, but FDA’s stringent ...
IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at IN8bio is a clinical-stage biopharmaceutical company ...